Literature DB >> 29595430

Surveillance Software and Prospective Audit and Feedback Rounds Advance Antimicrobial Stewardship at an Acute Care Community Hospital.

Anna Lee1, Susan John2, Reena Lovinsky3.   

Abstract

Antimicrobial stewardship is a key strategy to facilitate judicious antimicrobial use. Software that can amalgamate prescribing and microbiology information in near real-time reporting and track antimicrobial resistance patterns aids timely interventions. This article examines the impact of a clinical surveillance software used to identify patients for prospective audit and feedback rounds by an antimicrobial stewardship team on antibiotic utilization, patient outcomes and workload efficiencies at an acute care community hospital. Results from a general internal medicine unit show statistically significant reductions in the use of broad-spectrum antibiotics and antibiotic expenditures, with no untoward changes in key clinical and patient safety outcomes.
© 2018 Longwoods Publishing.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29595430     DOI: 10.12927/hcq.2018.25421

Source DB:  PubMed          Journal:  Healthc Q        ISSN: 1710-2774


  2 in total

Review 1.  In-Hospital Macro-, Meso-, and Micro-Drivers and Interventions for Antibiotic Use and Resistance: A Rapid Evidence Synthesis of Data from Canada and Other OECD Countries.

Authors:  Rosa Stalteri Mastrangelo; Anisa Hajizadeh; Thomas Piggott; Mark Loeb; Michael Wilson; Luis Enrique Colunga Lozano; Yetiani Roldan; Hussein El-Khechen; Anna Miroshnychenko; Priya Thomas; Holger J Schünemann; Robby Nieuwlaat
Journal:  Can J Infect Dis Med Microbiol       Date:  2022-03-16       Impact factor: 2.585

2.  General practitioners' accounts of negotiating antibiotic prescribing decisions with patients: a qualitative study on what influences antibiotic prescribing in low, medium and high prescribing practices.

Authors:  Marieke M van der Zande; Melanie Dembinsky; Giovanni Aresi; Tjeerd P van Staa
Journal:  BMC Fam Pract       Date:  2019-12-10       Impact factor: 2.497

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.